Shu Min Ho

Most recently, Shu Min has been honored with a position in the Global Investigations Review (GIR) 2024 “40 Under 40” list, which celebrates the “next crop of up-and-coming investigations specialists” around the globe. She has also been recognized in the Asian Legal Business Asia 40 Under 40 2024 list, which honors “the most accomplished lawyers in Asia under 40 years of age” whose involvement on major deals and key disputes has resulted in “accolades from their colleagues, superiors and clients.” In the 2024 and 2025 editions of Chambers Asia Pacific, Shu Min was named as an “Up and Coming” lawyer for Corporate Investigations/Anti-Corruption: International, earning commendations from clients that she is “always prepared and offers great insights”, and is “very talented and a pleasure to work with”. She is also highly praised for being “a very experienced lawyer who is also approachable and understands the industry well”, and who is able to “provide clear and succinct advice on all ABAC matters”. Shu Min is further recognized as a “Future Star” for White Collar Crime - International Firms by Benchmark Litigation Asia-Pacific (2024-2025), a Recommended Lawyer for White Collar Crime by Legal 500 Asia Pacific (2023-2025) and as a “Rising Star” by Asian Legal Business’ Rising Stars Singapore 2022 List.

Shu Min’s representative experience includes:

• Advised one of the world’s largest healthcare companies on multiple investigations across Asia Pacific, Europe, the Middle East, and Africa, involving possible violations of anti-bribery laws and other compliance violations such as improper sales and tender arrangements, possible bribery of public officials, non-compliant advertising and promotion of healthcare products, improper grants and donations, hospital consignment issues, and other senior management misconduct.
• Advised a global conglomerate in a major cross-border internal investigation into financial and workplace misconduct and bribery allegations in relation to its APAC division, against the backdrop of a U.S. DOJ and SEC investigation.
• Advised a U.S.-listed medical device company in multiple investigations in China, in relation to alleged bribery, kickbacks, falsification of sales and financial records, and collusion with distributors.
• Advised a global communication solutions company in relation to multiple regulatory investigations and litigation arising out of financial irregularities within its European subsidiary.
• Advised U.S.-listed and other multinational corporations in the life sciences, technology, sports, and entertainment sectors in relation to compliance with anti-bribery and corruption, antitrust, anti-money laundering, data privacy and cybersecurity, and sector-specific regulatory requirements (including interactions with government officials, advertising and promotion, sponsorships, donations, and third-party due diligence).
• Advised numerous clients in the medical device, pharmaceutical, consumer health, nutritional and food sectors on regulatory compliance, including marketing and advertising, labeling claims/requirements, and product withdrawals.
• Acted for two sets of receivers appointed by the English High Court in a commercial fraud case worth over US$6 billion, including advising on asset-tracing and -recovery operations and the recognition and enforcement of judgments in Europe and offshore jurisdictions such as the British Virgin Islands, the Seychelles, and Belize.